drugset / Trial / NCT02768298

Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

NCT02768298

Phase 4 Completed 201 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study was to determine the effect of LCZ696 vs. enalapril on improvement of exercise capacity in patients with chronic heart failure with reduced ejection fraction.

Timeline

Start
2016-07-12
Primary completion
2019-11-25
Completion
2019-11-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enalapril Other / unclassified 10 mg Oral
Subject LCZ696 Unknown 200 mg Oral